- Home
- SRBK vs ADCT Comparison
SRBK vs ADCT Comparison
Compare SRBK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRBK | ADCT |
|---|---|---|
| Founded | 1887 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.8M | 136.1M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRBK | ADCT |
|---|---|---|
| Price | $19.15 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 31.0K | ★ 1.3M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 138.36 | 30.86 |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $61.84 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $13.55 | $0.78 |
| 52 Week High | $20.20 | $4.98 |
Technical Indicators
Market Signals| Indicator | SRBK | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 39.49 |
| Support Level | $18.74 | $0.78 |
| Resistance Level | $19.61 | $1.45 |
| Average True Range (ATR) | 0.47 | 0.09 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 33.89 | 20.75 |
Price Performance
Historical ComparisonAbout SRBK SR Bancorp Inc.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).